Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Hold" Rating from Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Free Report) in a report published on Friday,Benzinga reports.

A number of other equities analysts also recently weighed in on the company. Leerink Partners set a $6.00 target price on Lexicon Pharmaceuticals and gave the company an "outperform" rating in a report on Friday, October 18th. HC Wainwright reiterated a "buy" rating and issued a $6.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $6.00.

Lexicon Pharmaceuticals Trading Up 11.9 %

Lexicon Pharmaceuticals stock traded up $0.09 during midday trading on Friday, reaching $0.86. The stock had a trading volume of 9,985,854 shares, compared to its average volume of 4,373,029. Lexicon Pharmaceuticals has a twelve month low of $0.73 and a twelve month high of $3.73. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The firm has a market cap of $212.60 million, a price-to-earnings ratio of -1.15 and a beta of 1.24. The firm's fifty day simple moving average is $1.53 and its two-hundred day simple moving average is $1.70.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The business had revenue of $1.75 million during the quarter, compared to analyst estimates of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. During the same period last year, the business earned ($0.21) EPS. Equities analysts anticipate that Lexicon Pharmaceuticals will post -0.69 EPS for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Barclays PLC increased its stake in shares of Lexicon Pharmaceuticals by 391.6% during the 3rd quarter. Barclays PLC now owns 193,873 shares of the biopharmaceutical company's stock worth $304,000 after purchasing an additional 154,436 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Lexicon Pharmaceuticals by 8.4% in the third quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company's stock worth $5,534,000 after purchasing an additional 273,436 shares in the last quarter. XTX Topco Ltd acquired a new position in Lexicon Pharmaceuticals during the third quarter worth $126,000. State Street Corp lifted its position in shares of Lexicon Pharmaceuticals by 6.8% in the third quarter. State Street Corp now owns 2,471,215 shares of the biopharmaceutical company's stock worth $3,880,000 after buying an additional 157,738 shares during the last quarter. Finally, Atom Investors LP acquired a new stake in shares of Lexicon Pharmaceuticals in the third quarter worth about $122,000. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.